LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia - Arix Bioscience

Close Navigation

About Strategy Team Portfolio Insights Media Contact

Overlay

LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia

2nd June 2021

Portfolio

This post references, or is about LogicBio. Find out more by clicking below

Cambridge, MA, US

Useful Tools

Download, print or share this article

Print

Print Article Email

Email

Print

Share Article